Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.’s share was trading at $8.33 as of June 9th. BCRX’s trailing and forward P/E were 7.46 and 72.99 respectively according to Yahoo Finance.
Copyright: dolgachov / 123RF Stock Photo
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BCRX is rated Bullish with a $22.00 target implying +140% upside as it evolves into a diversified rare disease leader in hereditary angioedema (HAE) across oral and injectable modalities.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The market is mispricing the combined ORLADEYO and navenibart franchise by viewing oral and injectable therapies as substitutes rather than complementary, creating a clear sum-of-the-parts opportunity. ORLADEYO anchors the business with $600M+ in recurring revenue, 21% growth, and APeX-S data demonstrating a 91% reduction in attack rates alongside a strong safety profile. Navenibart adds a differentiated twice-yearly injectable showing a 92% reduction in Phase 1b, expanding full-spectrum HAE coverage and reducing patient churn to competitors.
This dual-modality strategy is reinforced by orphan drug exclusivity, ORLADEYO patent protection through 2035, and the integration of biologics capabilities via the Astria acquisition. Near-term catalysts include BCX17725 Netherton syndrome Phase 1 Part 4 data in late 2026 and continued advancement of navenibart toward Phase 3 readouts and a 2027 BLA submission. Financial performance remains stable with Q1 2026 revenue of $156.4 million, full-year guidance of $625–$645 million, and a $160 million cash position strengthened by prior debt reduction.
The bull case assumes ORLADEYO reaches $1.1 billion in peak sales and navenibart contributes $650 million, supporting a re-rating toward $32–$35 per share. The bear case implies ~$5 per share if competitive pressure accelerates and growth decelerates. Overall, BioCryst presents a high-conviction bullish re-rating opportunity driven by durable rare disease demand, expanding pipeline optionality, strong clinical validation, and multiple catalysts extending through 2027.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy-driven gene editing commercialization and pipeline optionality across oncology and in vivo editing. CRSP’s stock price has appreciated by approximately 25.65% since our coverage. BioEquity Watch’s Substack shares a similar view but emphasizes BioCryst Pharmaceuticals (BCRX)’s rare disease HAE re-rating and dual-modality franchise expansion.
BioCryst Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 47 hedge fund portfolios held BCRX at the end of the first quarter which was 53 in the previous quarter. While we acknowledge the risk and potential of BCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BCRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
